Dual-tracer PET/CT protocol with [
Dual-tracer PET/CT
FAPI
FDG
Functional tissue volume
Gross tumor volume
Journal
Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]
ISSN: 1439-099X
Titre abrégé: Strahlenther Onkol
Pays: Germany
ID NLM: 8603469
Informations de publication
Date de publication:
16 Aug 2023
16 Aug 2023
Historique:
received:
04
04
2023
accepted:
05
07
2023
medline:
16
8
2023
pubmed:
16
8
2023
entrez:
16
8
2023
Statut:
aheadofprint
Résumé
Fibroblast activation protein (FAP) detected by positron-emission tomography (PET) using fibroblast activation protein inhibitor (FAPI) appears to be a promising target for cancer imaging, staging, and therapy, providing added value and strength as a complement to [ A total of 19 patients with head and neck and gastrointestinal cancers received initial [ The diagnostic performance of dual-tracer compared to single-tracer PET/CT was equal in 13 patients and superior in 6 patients. The mean TBRs of tumors and metastases in dual-tracer PET/CTs were mostly higher compared to single-tracer PET/CT using maximal count rates (CRmax). GTV and FTV were significantly larger when measured on dual-tracer compared to single-tracer PET/CT. Dual-tracer PET/CT with [
Identifiants
pubmed: 37584717
doi: 10.1007/s00066-023-02117-2
pii: 10.1007/s00066-023-02117-2
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2023. The Author(s).
Références
Santi A, Kugeratski FG, Zanivan S (2018) Cancer associated Fibroblasts: the architects of stroma remodeling. Proteomics 18:e1700167. https://doi.org/10.1002/pmic.201700167
doi: 10.1002/pmic.201700167
pubmed: 29280568
Garin-Chesa P, Old LJ, Rettig WJ (1990) Cell surface glycoprotein of reactive stromal fibroblasts as a potential antibody target in human epithelial cancers. Proc Natl Acad Sci U S A 87:7235–7239. https://doi.org/10.1073/pnas.87.18.7235
doi: 10.1073/pnas.87.18.7235
pubmed: 2402505
Kratochwil C, Flechsig P, Lindner T, Abderrahim L, Altmann A, Mier W et al (2019) (68)ga-FAPI PET/CT: tracer uptake in 28 different kinds of cancer. J Nucl Med 60:801–805. https://doi.org/10.2967/jnumed.119.227967
doi: 10.2967/jnumed.119.227967
pubmed: 30954939
Rettig WJ, Garin-Chesa P, Healey JH, Su SL, Ozer HL, Schwab M et al (1993) Regulation and heteromeric structure of the fibroblast activation protein in normal and transformed cells of mesenchymal and neuroectodermal origin. Cancer Res 53:3327–3335
pubmed: 8391923
Windisch P, Zwahlen DR, Koerber SA, Giesel FL, Debus J, Haberkorn U et al (2020) Clinical results of fibroblast activation protein (FAP) specific PET and implications for radiotherapy planning: systematic review. Cancers. https://doi.org/10.3390/cancers12092629
doi: 10.3390/cancers12092629
pubmed: 33374564
Lindner T, Loktev A, Altmann A, Giesel F, Kratochwil C, Debus J et al (2018) Development of Quinoline-based theranostic ligands for the targeting of fibroblast activation protein. J Nucl Med 59:1415–1422. https://doi.org/10.2967/jnumed.118.210443
doi: 10.2967/jnumed.118.210443
pubmed: 29626119
Meyer C, Dahlbom M, Lindner T, Vauclin S, Mona C, Slavik R et al (2020) Radiation dosimetry and biodistribution of (68)ga-FAPI-46 PET imaging in cancer patients. J Nucl Med 61:1171–1177. https://doi.org/10.2967/jnumed.119.236786
doi: 10.2967/jnumed.119.236786
pubmed: 31836685
Ballal S, Yadav MP, Moon ES, Kramer VS, Roesch F, Kumari S et al (2021) Biodistribution, pharmacokinetics, dosimetry of [(68)Ga]Ga-DOTA.SA.FAPi, and the head-to-head comparison with [(18)F]F-FDG PET/CT in patients with various cancers. Eur J Nucl Med Mol Imaging 48:1915–1931. https://doi.org/10.1007/s00259-020-05132-y
doi: 10.1007/s00259-020-05132-y
pubmed: 33244617
Giesel FL, Kratochwil C, Schlittenhardt J, Dendl K, Eiber M, Staudinger F et al (2021) Head-to-head intra-individual comparison of biodistribution and tumor uptake of (68)Ga-FAPI and (18)F-FDG PET/CT in cancer patients. Eur J Nucl Med Mol Imaging. https://doi.org/10.1007/s00259-021-05307-1
doi: 10.1007/s00259-021-05307-1
pubmed: 34537893
Windisch P, Röhrich M, Regnery S, Tonndorf-Martini E, Held T, Lang K et al (2020) Fibroblast Activation Protein (FAP) specific PET for advanced target volume delineation in glioblastoma. Radiother Oncol 150:159–163. https://doi.org/10.1016/j.radonc.2020.06.040
doi: 10.1016/j.radonc.2020.06.040
pubmed: 32598977
Shi X, Xing H, Yang X, Li F, Yao S, Zhang H et al (2021) Fibroblast imaging of hepatic carcinoma with (68)Ga-FAPI-04 PET/CT: a pilot study in patients with suspected hepatic nodules. Eur J Nucl Med Mol Imaging 48:196–203. https://doi.org/10.1007/s00259-020-04882-z
doi: 10.1007/s00259-020-04882-z
pubmed: 32468254
Wegen S, van Heek L, Linde P, Claus K, Akuamoa-Boateng D, Baues C et al (2022) Head-to-head comparison of [(68) ga]ga-FAPI-46-PET/CT and [(18)F]F-FDG-PET/CT for radiotherapy planning in head and neck cancer. Mol Imaging Biol. https://doi.org/10.1007/s11307-022-01749-7
doi: 10.1007/s11307-022-01749-7
pubmed: 35771317
Ristau J, Giesel FL, Haefner MF, Staudinger F, Lindner T, Merkel A et al (2020) Impact of primary staging with fibroblast activation protein specific enzyme inhibitor (FAPI)-PET/CT on radio-oncologic treatment planning of patients with esophageal cancer. Mol Imaging Biol 22:1495–1500. https://doi.org/10.1007/s11307-020-01548-y
doi: 10.1007/s11307-020-01548-y
pubmed: 33063132
Hu X, Zhou T, Ren J, Duan J, Wu H, Liu X et al (2022) Response prediction using (18)F-FAPI-04 PET/CT in patients with esophageal squamous cell carcinoma treated with concurrent chemoradiotherapy. J Nucl Med. https://doi.org/10.2967/jnumed.122.264638
doi: 10.2967/jnumed.122.264638
pubmed: 36229183
Liu F, Qi L, Liu B, Liu J, Zhang H, Che D et al (2015) Fibroblast activation protein overexpression and clinical implications in solid tumors: a meta-analysis. PLoS ONE 10:e116683. https://doi.org/10.1371/journal.pone.0116683
doi: 10.1371/journal.pone.0116683
pubmed: 25775399
Lapa C, Nestle U, Albert NL, Baues C, Beer A, Buck A et al (2021) Value of PET imaging for radiation therapy. Strahlenther Onkol 197:1–23. https://doi.org/10.1007/s00066-021-01812-2
doi: 10.1007/s00066-021-01812-2
pubmed: 34259912
Schiffner C, Christiansen H, Brandes I, Grannas G, Wichmann J, Merten R (2022) Neoadjuvant versus definitive radiochemotherapy of locoregionally advanced oesophageal cancer—who benefits? Strahlenther Onkol 198:1062–1071. https://doi.org/10.1007/s00066-022-01929-y
doi: 10.1007/s00066-022-01929-y
pubmed: 35416495
Herter JM, Kiljan M, Kunze S, Reinscheid M, Ibruli O, Cai J et al (2023) Influence of chemoradiation on the immune microenvironment of cervical cancer patients. Strahlenther Onkol 199:121–130. https://doi.org/10.1007/s00066-022-02007-z
doi: 10.1007/s00066-022-02007-z
pubmed: 36251031
Roth KS, Voltin CA, van-Heek L, Wegen S, Schomaecker K, Fischer T et al (2022) Dual-tracer PET/CT protocol with [(18)F]-FDG and [(68)Ga]Ga-FAPI-46 for cancer imaging—a proof of concept. J Nucl Med. https://doi.org/10.2967/jnumed.122.263835
doi: 10.2967/jnumed.122.263835
pubmed: 35422446
Gregoire V, Evans M, Le QT, Bourhis J, Budach V, Chen A et al (2018) Delineation of the primary tumour Clinical Target Volumes (CTV-P) in laryngeal, hypopharyngeal, oropharyngeal and oral cavity squamous cell carcinoma: AIRO, CACA, DAHANCA, EORTC, GEORCC, GORTEC, HKNPCSG, HNCIG, IAG-KHT, LPRHHT, NCIC CTG, NCRI, NRG Oncology, PHNS, SBRT, SOMERA, SRO, SSHNO, TROG consensus guidelines. Radiother Oncol 126:3–24. https://doi.org/10.1016/j.radonc.2017.10.016
doi: 10.1016/j.radonc.2017.10.016
pubmed: 29180076
Wu AJ, Bosch WR, Chang DT, Hong TS, Jabbour SK, Kleinberg LR et al (2015) Expert consensus contouring guidelines for intensity modulated radiation therapy in esophageal and gastroesophageal junction cancer. Int J Radiat Oncol Biol Phys 92:911–920. https://doi.org/10.1016/j.ijrobp.2015.03.030
doi: 10.1016/j.ijrobp.2015.03.030
pubmed: 26104943
Kessler L, Ferdinandus J, Hirmas N, Zarrad F, Nader M, Kersting D et al (2022) Pitfalls and common findings in (68)ga-FAPI PET: a pictorial analysis. J Nucl Med 63:890–896. https://doi.org/10.2967/jnumed.121.262808
doi: 10.2967/jnumed.121.262808
pubmed: 34620730
Qin C, Shao F, Gai Y, Liu Q, Ruan W, Liu F et al (2022) (68)Ga-DOTA-FAPI-04 PET/MR in the Evaluation of Gastric Carcinomas: Comparison with (18)F-FDG PET/CT. J Nucl Med 63:81–88. https://doi.org/10.2967/jnumed.120.258467
doi: 10.2967/jnumed.120.258467
pubmed: 33863819
Kuyumcu S, Sanli Y, Subramaniam RM (2021) Fibroblast-activated protein inhibitor PET/CT: cancer diagnosis and management. Front Oncol 11:758958. https://doi.org/10.3389/fonc.2021.758958
doi: 10.3389/fonc.2021.758958
pubmed: 34858834
Gu B, Xu X, Zhang J, Ou X, Xia Z, Guan Q et al (2022) The added value of (68)ga-FAPI PET/CT in patients with head and neck cancer of unknown primary with (18)F-FDG-negative findings. J Nucl Med 63:875–881. https://doi.org/10.2967/jnumed.121.262790
doi: 10.2967/jnumed.121.262790
pubmed: 34593594
Liu H, Hu Z, Yang X, Dai T, Chen Y (2022) Comparison of [(68)ga]ga-DOTA-FAPI-04 and [(18)F]FDG uptake in esophageal cancer. Front Oncol 12:875081. https://doi.org/10.3389/fonc.2022.875081
doi: 10.3389/fonc.2022.875081
pubmed: 35785188
Chen X, Wei M, Wang S, Yang Z, Wang X (2021) Characterizing concomitant follicular lymphoma and gastric carcinoma using 68ga-FAPI-04 and 18F-FDG PET/CT. Clin Nucl Med. https://doi.org/10.1097/rlu.0000000000003781
doi: 10.1097/rlu.0000000000003781
pubmed: 34606485
Mokoala K, Emil N, Lawal I, Antke C, Giesel FL, Sathekge M (2022) (68)Ga]Ga-FAPI versus [(18)F]F-FDG in malignant melanoma: complementary or counterpoint? Eur J Nucl Med Mol Imaging 49:2445–2446. https://doi.org/10.1007/s00259-022-05702-2
doi: 10.1007/s00259-022-05702-2
pubmed: 35137262
Kessler L, Ferdinandus J, Hirmas N, Bauer S, Dirksen U, Zarrad F et al (2022) (68)ga-FAPI as a diagnostic tool in sarcoma: data from the (68)ga-FAPI PET prospective observational trial. J Nucl Med 63:89–95. https://doi.org/10.2967/jnumed.121.262096
doi: 10.2967/jnumed.121.262096
pubmed: 33931468
Pak K, Cheon GJ, Nam HY, Kim SJ, Kang KW, Chung JK et al (2014) Prognostic value of metabolic tumor volume and total lesion glycolysis in head and neck cancer: a systematic review and meta-analysis. J Nucl Med 55:884–890. https://doi.org/10.2967/jnumed.113.133801
doi: 10.2967/jnumed.113.133801
pubmed: 24752671
Gopal A, Xi Y, Subramaniam RM, Pinho DF (2021) Intratumoral metabolic heterogeneity and other quantitative (18)F-FDG PET/CT parameters for prognosis prediction in esophageal cancer. Radiol Imaging Cancer 3:e200022. https://doi.org/10.1148/rycan.2020200022
doi: 10.1148/rycan.2020200022
pubmed: 33778756
Li Y, Zschaeck S, Lin Q, Chen S, Chen L, Wu H (2019) Metabolic parameters of sequential 18F-FDG PET/CT predict overall survival of esophageal cancer patients treated with (chemo‑) radiation. Radiat Oncol 14:35. https://doi.org/10.1186/s13014-019-1236-x
doi: 10.1186/s13014-019-1236-x
pubmed: 30782182
Zhao L, Chen S, Pang Y, Dai Y, Hu S, Lin L et al (2021) (68)Ga-fibroblast activation protein inhibitor PET/CT on gross tumour volume delineation for radiotherapy planning of oesophageal cancer. Radiother Oncol 158:55–61. https://doi.org/10.1016/j.radonc.2021.02.015
doi: 10.1016/j.radonc.2021.02.015
pubmed: 33621587
Sahai E, Astsaturov I, Cukierman E, DeNardo DG, Egeblad M, Evans RM et al (2020) A framework for advancing our understanding of cancer-associated fibroblasts. Nat Rev Cancer 20:174–186. https://doi.org/10.1038/s41568-019-0238-1
doi: 10.1038/s41568-019-0238-1
pubmed: 31980749
Wang Z, Tang Y, Tan Y, Wei Q, Yu W (2019) Cancer-associated fibroblasts in radiotherapy: challenges and new opportunities. Cell Commun Signal 17:47. https://doi.org/10.1186/s12964-019-0362-2
doi: 10.1186/s12964-019-0362-2
pubmed: 31101063